Equities research analysts expect Tandem Diabetes Care Inc (NASDAQ:TNDM) to post ($1.28) earnings per share for the current quarter, Zacks reports. Two analysts have made estimates for Tandem Diabetes Care’s earnings, with estimates ranging from ($1.37) to ($1.19). Tandem Diabetes Care posted earnings per share of ($4.80) in the same quarter last year, which would indicate a positive year over year growth rate of 73.3%. The business is scheduled to issue its next quarterly earnings report after the market closes on Thursday, March 1st.
On average, analysts expect that Tandem Diabetes Care will report full year earnings of ($15.15) per share for the current year, with EPS estimates ranging from ($16.99) to ($13.31). For the next financial year, analysts forecast that the company will post earnings of ($4.97) per share, with EPS estimates ranging from ($6.15) to ($2.87). Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Tandem Diabetes Care.
A number of brokerages have recently weighed in on TNDM. Zacks Investment Research cut Tandem Diabetes Care from a “buy” rating to a “hold” rating in a research note on Friday, January 5th. Robert W. Baird reaffirmed a “hold” rating and issued a $3.00 price objective on shares of Tandem Diabetes Care in a research note on Sunday, November 19th. Five research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $11.29.
In related news, CEO Kim D. Blickenstaff bought 750,000 shares of the stock in a transaction that occurred on Friday, February 9th. The stock was purchased at an average cost of $2.00 per share, with a total value of $1,500,000.00. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Christopher J. Twomey bought 75,000 shares of the stock in a transaction that occurred on Friday, February 9th. The shares were bought at an average cost of $2.00 per share, with a total value of $150,000.00. The disclosure for this purchase can be found here. Insiders own 20.90% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its stake in Tandem Diabetes Care by 2.7% during the 2nd quarter. Vanguard Group Inc. now owns 1,233,607 shares of the medical device company’s stock worth $987,000 after purchasing an additional 32,991 shares in the last quarter. Russell Investments Group Ltd. grew its stake in Tandem Diabetes Care by 13.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 659,993 shares of the medical device company’s stock worth $482,000 after purchasing an additional 78,748 shares in the last quarter. Finally, Wedbush Securities Inc. grew its stake in Tandem Diabetes Care by 88.6% during the 3rd quarter. Wedbush Securities Inc. now owns 188,877 shares of the medical device company’s stock worth $138,000 after purchasing an additional 88,709 shares in the last quarter.
Shares of Tandem Diabetes Care (TNDM) traded up $0.02 during midday trading on Wednesday, hitting $2.43. The stock had a trading volume of 739,479 shares, compared to its average volume of 1,010,000. Tandem Diabetes Care has a twelve month low of $2.14 and a twelve month high of $26.00. The company has a debt-to-equity ratio of -2.70, a current ratio of 1.90 and a quick ratio of 0.88. The firm has a market capitalization of $24.79, a PE ratio of -0.12 and a beta of 0.44.
TRADEMARK VIOLATION NOTICE: This story was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/17/zacks-brokerages-expect-tandem-diabetes-care-inc-tndm-will-announce-earnings-of-1-28-per-share.html.
Tandem Diabetes Care Company Profile
Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).
Get a free copy of the Zacks research report on Tandem Diabetes Care (TNDM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.